First Approval of Pacritinib as a Selective Janus Associated Kinase-2 Inhibitor for the Treatment of Patients with Myelofibrosis.
Sign Up to like & getrecommendations! Published in 2023 at "Anti-cancer agents in medicinal chemistry"
DOI: 10.2174/1871520623666230320120915
Abstract: In this short perspective, the chemical structure, physical properties, synthesis, mechanism of action, and pharmacokinetic profile of pacritinib are summarized. It is an orally bioavailable and isoform-selective JAK-2 inhibitor for treating patients with myelofibrosis. read more here.
Keywords: inhibitor; pacritinib selective; pacritinib; first approval ... See more keywords